APA
Zastrozhin M. S., Grishina E. A., Denisenko N. P., Skryabin V. Y., Markov D. D., Savchenko L. M., Bryun E. A. & Sychev D. A. (2018). Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. : Pharmacogenomics and personalized medicine.
Chicago
Zastrozhin Mikhail Sergeevich, Grishina Elena Anatolievna, Denisenko Nataliya Petrovna, Skryabin Valentin Yurievich, Markov Dmitry Dmitrievich, Savchenko Ludmila Mikhailovna, Bryun Evgeny Alekseevich and Sychev Dmitry Alekseevich. 2018. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. : Pharmacogenomics and personalized medicine.
Harvard
Zastrozhin M. S., Grishina E. A., Denisenko N. P., Skryabin V. Y., Markov D. D., Savchenko L. M., Bryun E. A. and Sychev D. A. (2018). Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. : Pharmacogenomics and personalized medicine.
MLA
Zastrozhin Mikhail Sergeevich, Grishina Elena Anatolievna, Denisenko Nataliya Petrovna, Skryabin Valentin Yurievich, Markov Dmitry Dmitrievich, Savchenko Ludmila Mikhailovna, Bryun Evgeny Alekseevich and Sychev Dmitry Alekseevich. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. : Pharmacogenomics and personalized medicine. 2018.